Aurinia Pharmaceuticals Inc AUPH.OQ AUPH.O is expected to show a rise in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024
The Victoria British Columbia-based company is expected to report a 5.8% increase in revenue to $57.693 million from $54.52 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Aurinia Pharmaceuticals Inc is for earnings of 2 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is 10.00, above its last closing price of $7.24.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | 0.01 | 0.01 | Met | 20 | |
Mar. 31 2024 | -0.18 | -0.14 | -0.03 | Beat | 78 |
Dec. 31 2023 | -0.16 | -0.19 | Missed | -16.3 | |
Sep. 30 2023 | -0.16 | -0.17 | -0.09 | Beat | 46.2 |
Jun. 30 2023 | -0.18 | -0.18 | -0.08 | Beat | 56.4 |
Jan. 1 0001 | -0.22 | -0.22 | -0.18 | Beat | 18.7 |
Dec. 31 2022 | -0.27 | -0.27 | -0.18 | Beat | 34 |
Sep. 30 2022 | -0.17 | -0.17 | -0.06 | Beat | 64.4 |
This summary was machine generated October 29 at 13:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments